Table 2.
Clinical trial availability and doctor's recommendation for participation reported by AYA cancer survivors according to selected characteristics, AYA HOPE Study
| Knew about availability of clinical trials 1 | A clinical trial was available2 | Doctor recommended participation in a clinical trial3 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Yes | No | Yes | No | Yes | No | |||||||
| Characteristic | (n=191) | (n=324) | (n=86) | (n=105) | (n=52) | (n=26) | ||||||
| N | % | N | % | N | % | N | % | N | % | N | % | |
| Cancer Type | ||||||||||||
| Acute lymphocytic leukemia | 13 | (61.9)4 | 8 | (38.1) | 9 | (69.2) | # | # | 7 | (100.0) | 0 | (0.0) |
| Germ cell tumor | 66 | (32.8) | 135 | (67.2) | 18 | (27.3) | 48 | (72.7) | 12 | (70.6) | 5 | (29.4) |
| Hodgkin lymphoma | 53 | (37.6) | 88 | (62.4) | 29 | (54.7) | 24 | (45.3) | 17 | (63.0) | 10 | (37.0) |
| Non-Hodgkin lymphoma | 48 | (37.5) | 80 | (62.5) | 21 | (43.8) | 27 | (56.3) | 11 | (61.1) | 7 | (38.9) |
| Sarcoma | 11 | (45.8) | 13 | (54.2) | 9 | (81.8) | # | 5 | (55.6) | # | ||
| AJCC stage | ||||||||||||
| I | 66 | (32.5) | 137 | (67.5) | 17 | (25.8) | 49 | (74.2) | 11 | (68.8) | 5 | (31.3) |
| II | 53 | (42.1) | 73 | (57.9) | 27 | (50.9) | 26 | (49.1) | 15 | (62.5) | 9 | (37.5) |
| III | 30 | (41.1) | 43 | (58.9) | 16 | (53.3) | 14 | (46.7) | 10 | (71.4) | # | |
| IV | 19 | (29.2) | 46 | (70.8) | 12 | (63.2) | 7 | (36.8) | 7 | (58.3) | 5 | (41.7) |
| Unknown | 23 | 25 | 14 | 9 | 9 | # | ||||||
| Sex | ||||||||||||
| Male | 114 | (34.9) | 213 | (65.1) | 48 | (42.1) | 66 | (57.9) | 28 | (62.2) | 17 | (37.8) |
| Female | 77 | (41.0) | 111 | (59.0) | 38 | (49.4) | 39 | (50.6) | 24 | (72.7) | 9 | (27.3) |
| Age at Diagnosis, yrs | ||||||||||||
| 15-19 | 31 | (47.0) | 35 | (53.0) | 18 | (58.1) | 13 | (41.9) | 14 | (87.5) | # | |
| 20-24 | 34 | (37.4) | 57 | (62.6) | 11 | (32.4) | 23 | (67.6) | 9 | (100.0) | 0 | (0.0) |
| 25-29 | 56 | (42.7) | 75 | (57.3) | 26 | (46.4) | 30 | (53.6) | 13 | (56.5) | 10 | (43.5) |
| 30-34 | 38 | (33.0) | 77 | (67.0) | 13 | (34.2) | 25 | (65.8) | 5 | (38.5) | 8 | (61.5) |
| 35-39 | 32 | (28.6) | 80 | (71.4) | 18 | (56.3) | 14 | (43.8) | 11 | (64.7) | 6 | (35.3) |
| Race/Ethnicity | ||||||||||||
| White, Hispanic | 49 | (45.4) | 59 | (54.6) | 27 | (55.1) | 22 | (44.9) | 14 | (63.6) | 8 | (36.4) |
| White, Non-Hispanic | 106 | (34.9) | 198 | (65.1) | 41 | (38.7) | 65 | (61.3) | 26 | (66.7) | 13 | (33.3) |
| Black | 18 | (40.9) | 26 | (59.1) | 10 | (55.6) | 8 | (44.4) | 8 | (88.9) | # | |
| Asian or Pacific Islander | 16 | (32.0) | 34 | (68.0) | 8 | (50.0) | 8 | (50.0) | # | # | ||
| Other | # | 7 | (77.8) | 0 | (0.0) | # | 0 | (0.0) | 0 | (0.0) | ||
| Employment and educational status prior to diagnosis | ||||||||||||
| Full-Time Work | 108 | (34.6) | 204 | (65.4) | 49 | (45.4) | 59 | (54.6) | 27 | (58.7) | 19 | (41.3) |
| Full-Time School | 54 | (45.4) | 65 | (54.6) | 27 | (50.0) | 27 | (50.0) | 20 | (87.0) | # | # |
| Neither Full-Time Work or Full-Time School | 29 | (34.5) | 55 | (65.5) | 10 | (34.5) | 19 | (65.5) | 5 | (55.6) | # | # |
| Health insurance | ||||||||||||
| Not insured | 5 | (31.3) | 11 | (68.8) | # | # | # | # | # | # | ||
| Insured | 186 | (37.3) | 313 | (62.7) | 84 | (45.2) | 102 | (54.8) | 51 | (67.1) | 25 | (32.9) |
| Number of comorbid conditions | ||||||||||||
| 0 | 139 | (37.4) | 233 | (62.6) | 60 | (43.2) | 79 | (56.8) | 39 | (68.4) | 18 | (31.6) |
| 1 | 26 | (31.7) | 56 | (68.3) | 12 | (46.2) | 14 | (53.8) | 9 | (75.0) | # | |
| 2+ | 26 | (42.6) | 35 | (57.4) | 14 | (53.8) | 12 | (46.2) | # | 5 | (55.6) | |
| Physician Specialty | ||||||||||||
| Not Medical Oncology | 75 | (35.9) | 134 | (64.1) | 24 | (32.0) | 51 | (68.0) | 14 | (66.7) | 7 | (33.3) |
| Medical Oncology | 89 | (40.6) | 130 | (59.4) | 44 | (49.4) | 45 | (50.6) | 25 | (61.0) | 16 | (39.0) |
| Unknown | 27 | 60 | 18 | 9 | 13 | # | ||||||
| Treating Institution Characteristics | ||||||||||||
| Hospital type | ||||||||||||
| NCI Cancer Center | 31 | (36.5) | 54 | (63.5) | 15 | (48.4) | 16 | (51.6) | 11 | (78.6) | # | # |
| Other Cancer Center, Academic | 5 | (19.2) | 21 | (80.8) | # | (40.0) | # | (60.0) | 0 | (0.0) | # | # |
| Other Cancer Center, Non-Academic | 72 | (36.9) | 123 | (63.1) | 29 | (40.3) | 43 | (59.7) | 16 | (66.7) | 8 | (33.3) |
| No Cancer Center, Academic | 20 | (48.8) | 21 | (51.2) | 13 | (65.0) | 7 | (35.0) | 9 | (69.2) | # | # |
| No Cancer Center, Non-Academic | 56 | (43.1) | 74 | (56.9) | 23 | (41.1) | 33 | (58.9) | 12 | (54.5) | 10 | (45.5) |
| Unknown | 7 | 31 | # | # | # | # | # | # | 0 | |||
| Residency Training Program | ||||||||||||
| No/Unknown | 60 | (35.5) | 109 | (64.5) | 17 | (28.3) | 43 | (71.7) | 9 | (52.9) | 8 | (47.1) |
| Yes | 125 | (40.1) | 187 | (59.9) | 66 | (52.8) | 59 | (47.2) | 40 | (69.0) | 18 | (31.0) |
| Missing | 6 | 28 | 3 | 3 | 3 | 0 | ||||||
| Bed size | ||||||||||||
| <300 | 74 | (40.9) | 107 | (59.1) | 31 | (41.9) | 43 | (58.1) | 21 | (70.0) | 9 | (30.0) |
| 300-499 | 45 | (33.6) | 89 | (66.4) | 21 | (46.7) | 24 | (53.3) | 11 | (73.3) | # | # |
| 500+ | 56 | (39.2) | 87 | (60.8) | 26 | (46.4) | 30 | (53.6) | 15 | (60.0) | 10 | (40.0) |
| Unknown | 16 | 41 | 8 | 8 | 5 | # | ||||||
1
For the patient's type and stage of cancer
2
For the patient's type and stage of cancer. Calculated among the 191 patients who responded “Yes” regarding knowledge of availability of clinical trial
3
Calculated among the 78 patients who reported knowing that a clinical trial was available; 8 additional such patients did not respond to this item on the questionnaire
4
Row percentages are calculated separately for each clinical trial knowledge question
#
Data not shown due to cell size <5